BiondVax Pharmaceuticals Ltd. (BVXV): history, ownership, mission, how it works & makes money

From its founding in 2003 by Dr. Ron Babecoff on technology from Prof. Ruth Arnon to a dramatic pivot in 2021, BiondVax-now rebranded as Scinai Immunotherapeutics Ltd.-has moved from broad-coverage influenza vaccine trials to cutting-edge nanosized antibody (NanoAb) therapeutics, running a seven-country Phase 3 influenza study of 12,400 participants between 2018-2020 after a promising Phase IIb readout in 2017; leadership changed in March 2021 with CEO Amir Reichman steering the company toward NanoAbs, formalized by a strategic collaboration in December 2021 with the Max Planck Institute and University Medical Center Göttingen and an exclusive license with Max Planck Innovation for an anti‑IL‑17 NanoAb, followed by a September 2023 rebrand to Scinai and NASDAQ ticker transition from BVXV to SCNI, while the company leverages its Jerusalem GMP biologics facility to develop, manufacture and commercially position NanoAbs (and offer CDMO services) to generate revenues via licensing, milestone payments, royalties and product sales across indications such as COVID‑19, psoriasis, asthma and macular degeneration.

BiondVax Pharmaceuticals Ltd. (BVXV): Intro

• 2003 - Company founded by Dr. Ron Babecoff based on Prof. Ruth Arnon's technology.
• 2017 - Completed Phase IIb trial of its influenza vaccine candidate demonstrating broad strain coverage (multi-season/strain immunogenicity signals reported).
• 2018-2020 - Conducted a seven-country, 12,400-participant Phase 3 (M-030) trial of the universal influenza vaccine candidate; the trial did not meet its primary clinical endpoints.
• March 2021 - Amir Reichman appointed CEO; strategic pivot announced toward developing nanosized antibody (NanoAb) therapies.
• December 2021 - Strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Göttingen to develop COVID-19 NanoAb therapies.
• September 2023 - Rebranded as Scinai Immunotherapeutics Ltd., reflecting a broader focus on inflammation and immunology biologics.

• Public listing - Historically traded on Nasdaq (ticker BVXV) and the Tel Aviv Stock Exchange (TASE) as a small-cap biotech issuer; trading liquidity and float have varied over time.
• Shareholder profile - Typically a mix of institutional investors, retail holders, and insiders; ownership concentrations fluctuate with funding rounds and open-market activity.
• Governance - Board historically composed of scientific founders, independent directors and executive management; strategic direction shifted under CEO Amir Reichman in 2021.

• Original mission - Develop a broadly protective (universal) influenza vaccine leveraging conserved antigen constructs to reduce seasonal vaccine mismatch problems.
• Revised mission (post-2021) - Develop nanosized antibody (NanoAb) therapeutics and biologics targeting inflammation, infectious diseases (including COVID-19) and other immunology indications.

• Universal influenza vaccine program - Employed a multi-epitope antigen design intended to elicit cross-reactive antibodies and T-cell responses to conserved influenza proteins across strains and seasons.
• NanoAb therapeutics - Develops engineered nanosized antibodies (single-domain-like formats) intended to provide high tissue penetrance, potential cost-efficient manufacture, and modular targeting of viral or inflammatory epitopes.
• Collaborative R&D model - Partnerships with academic institutes (e.g., Max Planck, UMG) provide basic discovery, preclinical validation and shared technical platforms for NanoAb development.

• Grant and public funding - Non-dilutive support from governments, research agencies and collaborative grants for vaccine and therapeutic R&D.
• Collaborations and licensing - Revenue potential from research collaborations, milestone payments and licensing of IP to pharma partners (common in biotech development-stage companies).
• Equity financing - Capital raises (private placements, public offerings) to fund clinical trials and platform development; equity dilution is a common funding route.
• Service and subcontracts - Fee-for-service R&D work, preclinical validation, or contract research collaborations with academic partners.

• Revenue profile - Historically limited or non-material product revenue; primary expenditures have been R&D and clinical trial costs.
• Capital needs - Biotech stage transition (Phase III and platform pivots) typically requires substantial capital; companies in this position rely on financing rounds and partner funding.
• Risk profile - High clinical and regulatory risk demonstrated by the Phase III outcome; potential upside tied to successful NanoAb discovery, validation, and partnering/licensing deals.

BiondVax Pharmaceuticals Ltd. (BVXV): History

• Founded: early 2000s (Israel); grew through academic collaborations and clinical-stage programs.
• Core earlier program: Multimeric-001 (universal influenza vaccine candidate) with multiple Phase I/II studies completed.
• Rebrand: September 2023 - new name Scinai Immunotherapeutics Ltd., new ticker SCNI on NASDAQ.
• Listing status: Continues to be listed on NASDAQ under SCNI as of late 2025.

• Public listing: Historically traded on NASDAQ under BVXV; post-2023 trading under SCNI.
• Shareholder mix: Diverse blend of institutional investors, retail/individual shareholders, and insider holdings (management and directors).
• Post-rebrand ownership: No material structural change publicly reported; major institutional holders and retail investors remain part of the cap table.

• Mission: Develop and commercialize immunotherapies and vaccines targeting unmet needs in infectious disease and inflammatory conditions.
• How it works: R&D-driven model - discovery and preclinical development, clinical trials, strategic partnerships or licensing, and potential out-licensing or product commercialization.
• How it makes money: Primarily through milestone and licensing revenues from partners, grants and R&D funding, equity raises (public offerings/Private placements), and eventual product sales or royalties if/when assets reach commercialization.

BiondVax Pharmaceuticals Ltd. (BVXV) Ownership Structure

• BiondVax Pharmaceuticals Ltd. (BVXV) is committed to developing innovative immunotherapeutic products for the treatment of infectious and autoimmune diseases.
• The company's mission includes advancing a pipeline of nanosized antibody (NanoAb) therapies to address large, underserved patient populations.
• BiondVax values collaboration, as evidenced by partnerships with leading research institutions (analogous to collaborations such as the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen).
• The company emphasizes scientific excellence, aiming to develop "biobetter" therapeutics that overcome limitations of existing antibody therapies.
• BiondVax is dedicated to patient-centric solutions, focusing on treatments that offer safety, efficacy, and convenience.
• The company upholds integrity and transparency in its operations, ensuring compliance with regulatory standards and ethical practices.

• Platform: development of nanosized antibodies (NanoAbs) designed for improved tissue penetration, stability and manufacturability versus conventional monoclonal antibodies.
• Primary therapeutic focus: infectious diseases and selected autoimmune indications where broad, durable immune modulation is needed.
• Clinical strategy: progress lead candidates through IND-enabling studies and early clinical trials, then seek partnering or licensing for late-stage development and commercialization.

• R&D milestones and grants - non-dilutive funding for early-stage research and preclinical work.
• Licensing and partnerships - upfront payments, milestones and royalties from strategic collaborations for late-stage development and commercialization.
• Equity financing - public and private raises to fund clinical development and platform expansion.
• Potential M&A or asset sales - divestiture or sale of clinical-stage assets to larger pharma for capital and execution leverage.

BiondVax Pharmaceuticals Ltd. (BVXV): Mission and Values

• Founded in Israel; historically focused on universal influenza vaccine candidate M-001, later diversified through alliances and technology licensing.
• Publicly traded under ticker BVXV on OTC markets; ownership includes institutional investors, private holders, and Israeli biotech insiders.
• Corporate shifts in the 2020s saw strategic partnerships and technology transfers toward biologics and antibody-based therapeutics.

• Platform: Nanosized antibodies (NanoAbs / VHH / nanobodies) derived from camelids (alpacas) with single-domain antibody architecture (~12-15 kDa).
• Scientific collaborations: Joint R&D with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to access structural biology, engineering know‑how, and in vivo validation models.
• Advantages vs conventional mAbs:
  • Higher thermal and chemical stability (retain function after exposure to elevated temperatures and low pH).
  • Strong tissue penetration due to small size; potential for topical, intravitreal, inhaled, and systemic delivery.
  • High binding affinity and ability to target cryptic or concave epitopes inaccessible to full-length IgGs (KD ranges typically low‑nM to pM in optimized constructs).
• Manufacturing: Uses a GMP biologics manufacturing facility in Jerusalem for pilot and clinical‑scale production of NanoAbs, enabling rapid process development and cGMP batch release for IND-enabling studies.
• Development strategy: Biobetter approach-engineering improved versions of well‑validated targets and mechanisms from approved biologics to shorten translational risk and leverage known safety/efficacy paradigms.
• Pipeline focus: Multi-indication NanoAb candidates targeting acute infectious disease (including COVID‑19), inflammatory/autoimmune diseases (psoriasis, asthma), and ophthalmic disease (age-related macular degeneration, diabetic macular edema).

• NanoAb molecular weight: ~12-15 kDa (vs ~150 kDa for IgG1), enabling ~10× improved tissue penetration in some models.
• Typical binding affinities: engineered NanoAbs often achieve KD in low‑nM to sub‑nM/pM ranges for optimized clones.
• Manufacturing: recombinant expression yields in bacterial/yeast/mammalian hosts commonly range from tens to hundreds mg/L in early processes; clinical GMP processes scaled to multi‑gram batches as needed.
• Stability: NanoAbs can remain functional after weeks at 4-25°C and tolerate transient heat stress better than many full‑length antibodies.

• Technology licensing: out‑licensing NanoAb candidates or platform rights to pharmas/biotechs for specific indications or territories.
• Collaborative R&D and milestone payments: partnerships with academic institutes and pharma that provide upfront, R&D funding, milestones, and royalties.
• Manufacturing services: GMP biologics facility services for third parties (fee‑for‑service and contract manufacturing) where capacity and expertise are offered.
• Equity and grants: capital raises (public offerings, private placements), government grants (Israeli and EU research funds), and non‑dilutive funding tied to translational milestones.

• Leverages academic partnerships (Max Planck, UMC Göttingen) for structural and translational excellence while maintaining in‑house GMP capabilities to de‑risk CMC timelines.
• Biobetter focus reduces target and mechanism risk versus first‑in‑class approaches, improving partnering and licensing prospects.
• Small-format NanoAbs open new route-of-administration opportunities (inhaled, topical, intravitreal) that can create differentiated clinical and commercial profiles versus conventional antibodies.

BiondVax Pharmaceuticals Ltd. (BVXV): How It Works

• Founded: 2003 (Ness Ziona, Israel)
• Core technology: multi-epitope recombinant protein vaccines and immunotherapeutics (lead program historically: universal influenza candidate M-001)
• Public presence: listed on NASDAQ and the Tel Aviv Stock Exchange under ticker BVXV

• Development & commercialization of proprietary therapeutics and vaccines - potential revenue from product sales upon regulatory approval and market launch.
• Strategic collaborations and licensing agreements - upfront license fees, R&D funding, milestone payments and tiered royalties on future sales.
• Contract services / CDMO-like activities - providing development, process optimization and GMP manufacturing services to partners (where facilities and expertise permit).
• Manufacturing leverage - in-house production capabilities reduce COGS and improve margin capture when moving to commercial supply.
• Pipeline diversification - multiple candidate programs and external collaborations increase probability-weighted revenues and reduce single-product concentration risk.

• Exclusive license agreements: generate upfront fees and downstream milestones/royalties tied to development and commercialization success.
• Co-development partnerships: shared R&D costs and shared future revenues or royalties based on negotiated splits.
• Services contracts (fee-for-service): predictable, contractually-bound cash flow for development and manufacturing work.

• In-house manufacturing: lowers marginal production costs and supports higher gross margins versus fully outsourced supply.
• Strategic collaborations: de-risk capital intensity of late-stage trials via partner-funded studies and milestone payments.
• Portfolio diversification: increases probability of at least one commercial success and stabilizes long-term revenue profile.
• Scale and capacity utilization: fixed-cost absorption in manufacturing and development drives operating leverage as revenue grows.

• By combining proprietary vaccine/immunotherapeutic R&D with licensing and service offerings, BiondVax aims to create multiple near- and long-term revenue streams.
• Successful licensing deals and milestone captures materially de-risk the balance sheet and extend runway without dilutive financing.
• Home-grown manufacturing and CDMO-style services can convert fixed-capacity into contracted revenue, improving margins and valuation multiples.

BiondVax Pharmaceuticals Ltd. (BVXV): How It Makes Money

• Founded: 2003; public ticker: BVXV (Nasdaq OTC).
• Rebranding: completed September 2023 to reflect a strategic shift toward inflammation and immunology biological therapeutics.
• Headquarters: Israel; core focus: NanoAb and other immunotherapeutic platforms.

• Collaborative R&D agreements - upfront payments, milestone payments and staged research funding from academic and industry partners (company reports 3 active institutional collaborations as of 2024).
• Licensing & royalties - out-licensing of specific NanoAb assets or platform technologies in exchange for upfront fees, development milestones and tiered royalties on future sales.
• Manufacturing & CMO services - commercial-scale biologics manufacturing in-house, enabling fee-for-service production revenue and margin capture; facility utilization targeted to support both internal pipeline and third-party contracts.
• Equity & grant funding - non-dilutive grants and equity financings to fund clinical programs and scale manufacturing.

• Strategic repositioning: The September 2023 rebrand signaled a clear pivot to immunology and inflammation biologics, aligning R&D and commercial efforts toward higher-value therapeutic areas.
• Competitive edge: In-house manufacturing reduces third-party COGS exposure and shortens time-to-clinic for NanoAb candidates, improving potential margins on partnered or internal products.
• Pipeline diversification: Multiple NanoAb programs targeting different indications reduce single-product dependence and address significant unmet medical needs across immunology and infectious disease.
• Collaborative credibility: Partnerships with leading research institutions enhance translational capability and de-risk early development, supporting potential milestone-driven revenue.
• Growth outlook: Planned advancement of NanoAb programs toward IND-enabling studies, plus expansion of CMO services, positions the company for near- to mid-term value inflection events (preclinical to clinical transitions and licensing deals).